Press enter to begin your search

Valirx - Amends License for VAL201 with Cancer Research Technology

VAL
Mon, 20 Dec 2021, 12:20 GMT

Dr Suzy Dilly, CEO of Valirx, discusses the amendment of the VAL201 license which will allow ValiRx and TheoremRx Inc. to proceed to full license without further CRT involvement.

Dr Suzanne Dilly
Chief Executive Officer
VAL
61c053412087413a5328c414
SHOW MORE
FROM THIS COMPANY
Valirx - Amends License for VAL201 with Cancer Research Technology
VAL Mon, 20 Dec 2021, 12:20 GMT

ValiRx accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development.

Industry: Health Care

Contact: +44 (0)2476 796496
Barling Way
https://www.valirx.com/

Dr Suzy Dilly, CEO of Valirx, discusses the amendment of the VAL201 license which will allow ValiRx and TheoremRx Inc. to proceed to full license without further CRT involvement.

Dr Suzanne Dilly
Chief Executive Officer
POWERED BY